INTRODUCTION: Trilateral retinoblastoma (TRb) is an intracranial neurogenic tumor associated with unilateral or bilateral retinoblastoma and has very poor prognosis. Patients typically die from leptomeningeal tumor dissemination. CASE REPORT: A 3-year-old girl who had been diagnosed with TRb had a disseminated relapse after a tumorectomy, cerebrospinal irradiation, and conventional chemotherapy. The disseminated tumor disappeared after the first autologous peripheral blood stem cell transplantation (PBSCT) with high-dose melphalan and thiotepa. During the second complete remission, a second autologous PBSCT with high-dose busulfan and melphalan was performed. Seven months after the first PBSCT, the second relapse occurred, and we subsequently performed an allogeneic PBSCT with myeloablative chemotherapy consisting of melphalan, thiotepa, and cyclophosphamide. The patient showed clinical improvement after the allogeneic PBSCT. CONCLUSION: Although high-dose chemotherapies have a curative effect for some patients with TRb, the prognoses of disseminated tumors are still poor. Further examination of the high-dose chemotherapy is necessary for the time, the conditioning drugs, and the hematopoietic stem cell sources.
INTRODUCTION:Trilateral retinoblastoma (TRb) is an intracranial neurogenic tumor associated with unilateral or bilateral retinoblastoma and has very poor prognosis. Patients typically die from leptomeningeal tumor dissemination. CASE REPORT: A 3-year-old girl who had been diagnosed with TRb had a disseminated relapse after a tumorectomy, cerebrospinal irradiation, and conventional chemotherapy. The disseminated tumor disappeared after the first autologous peripheral blood stem cell transplantation (PBSCT) with high-dose melphalan and thiotepa. During the second complete remission, a second autologous PBSCT with high-dose busulfan and melphalan was performed. Seven months after the first PBSCT, the second relapse occurred, and we subsequently performed an allogeneic PBSCT with myeloablative chemotherapy consisting of melphalan, thiotepa, and cyclophosphamide. The patient showed clinical improvement after the allogeneic PBSCT. CONCLUSION: Although high-dose chemotherapies have a curative effect for some patients with TRb, the prognoses of disseminated tumors are still poor. Further examination of the high-dose chemotherapy is necessary for the time, the conditioning drugs, and the hematopoietic stem cell sources.
Authors: G Vassal; A Deroussent; O Hartmann; D Challine; E Benhamou; D Valteau-Couanet; L Brugières; C Kalifa; A Gouyette; J Lemerle Journal: Cancer Res Date: 1990-10-01 Impact factor: 12.701
Authors: Sridharan Gururangan; William P Petros; Tina Young Poussaint; Michael L Hancock; Peter C Phillips; Henry S Friedman; Lisa Bomgaars; Susan M Blaney; Larry E Kun; James M Boyett Journal: Clin Cancer Res Date: 2006-03-01 Impact factor: 12.531
Authors: R L Heideman; D E Cole; F Balis; J Sato; G H Reaman; R J Packer; L J Singher; L J Ettinger; A Gillespie; J Sam Journal: Cancer Res Date: 1989-02-01 Impact factor: 12.701
Authors: J Hara; Y Osugi; H Ohta; Y Matsuda; K Nakanishi; K Takai; H Fujisaki; S Tokimasa; M Fukuzawa; A Okada; S Okada Journal: Bone Marrow Transplant Date: 1998-07 Impact factor: 5.483